Hung-kai Kevin ChenMSc, MD, PhD
Kevin is the founder and Chief Executive Officer of Elixiron Immunotherapeutics. Over the course of his career, Kevin has been committed to advancing the development of breakthrough therapeutics from bench to bedside. Most recently, he served as Senior Vice President and Chief Medical Officer of Eusol Biotech Co., Ltd. Prior to Eusol, Kevin served as Director of Translational Medicine at Development Center for Biotechnology (DCB), Taiwan, where he championed the establishment of DCB’s immune-oncology portfolio including anti-PD-L1, anti-TIM3, and CSF1R inhibitor.
Prior to DCB, Kevin was Principal Scientist at GSK’s neuroscience R&D center in Shanghai. There, he led the preclinical development of small molecule drugs for multiple sclerosis and served as a biology leader for the clinical development of Refanezumab (Phase II). Prior to joining GSK, Kevin was an Assistant Investigator of Gladstone Institutes, San Francisco where he participated in an academia-industry collaborative project with Merck & Co., Inc. for developing small molecule drugs of Alzheimer’s disease.
Kevin earned his M.D. and Ph.D. from National Yang-Ming University and completed postdoctoral training at Baylor College of Medicine in Houston, Texas. Kevin has authored or co-authored several peer-reviewed manuscripts in the leading’s journals including Cell, Nature Medicine and Nature Genetics.